Screening for Alzheimer's Disease Studies
(TRAVELLER Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial seeks participants who may qualify for Alzheimer's disease studies by examining specific blood markers and testing memory. It does not involve new treatments but focuses on assessing each participant's memory abilities. Individuals who have recently noticed memory issues and are not reliant on others for basic daily activities may be suitable for this trial. Those with other neurological conditions or severe past head injuries may not qualify. As a Phase 3 trial, this study represents the final step before FDA approval, providing an opportunity to contribute to important research.
Do I have to stop taking my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Why are researchers excited about this trial?
Researchers are excited about this trial because it aims to improve how we screen for Alzheimer's disease by focusing on detecting pTau217 levels in the blood. Unlike current methods that rely heavily on cognitive testing and brain imaging, this trial is investigating a more accessible and less invasive approach. By measuring pTau217, a protein linked to Alzheimer's, researchers hope to identify the disease earlier and more accurately. This could lead to better outcomes by catching the condition before significant damage occurs.
Who Is on the Research Team?
Clinical Trials
Principal Investigator
Hoffmann-La Roche
Are You a Good Fit for This Trial?
This pre-screening study is for individuals who may have Alzheimer's disease or cognitive impairment and are interested in participating in future Roche interventional studies. Specific eligibility criteria details are not provided.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Assessment
Participants will be assessed for their concentration of pTau217 in blood and cognitive score in the International Shopping List Test (ISLT)
Follow-up
Participants are monitored for safety and effectiveness after assessment
What Are the Treatments Tested in This Trial?
Interventions
- No Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hoffmann-La Roche
Lead Sponsor
Dr. Levi Garraway
Hoffmann-La Roche
Chief Medical Officer since 2019
MD from the University of Basel
Dr. Thomas Schinecker
Hoffmann-La Roche
Chief Executive Officer since 2023
PhD in Molecular Biology from New York University